Results 141 to 150 of about 4,521 (193)

Transitional CXCL14+ cancer‐associated fibroblasts enhance tumour metastasis and confer resistance to EGFR‐TKIs, revealing therapeutic vulnerability to filgotinib in lung adenocarcinoma

Clinical and Translational Medicine
Background The heterogeneity of cancer‐associated fibroblasts (CAFs) has become a crucial focus in understanding cancer biology and treatment response, revealing distinct subpopulations with specific roles in tumor pathobiology. CAFs have also been shown
Weijiao Xu, Haitang Yang, Ke Xu, Anshun Zhu, Sean R R Hall, Yunxuan Jia, Baicheng Zhao, Enshuo Zhang, Gang Liu, Jianlin Xu, T. M. Marti, R. Peng, P. Dorn, Yongliang Niu, Xufeng Pan, Yajuan Zhang, Feng Yao   +16 more
semanticscholar   +1 more source

The Role of Filgotinib in Ulcerative Colitis and Crohn’s Disease

Immunotherapy, 2023
Filgotinib is an oral small molecule that selectively inhibits JAK1. It is already approved for the treatment of moderately to severely active ulcerative colitis (UC). Ongoing studies are evaluating the efficacy and safety of filgotinib in Crohn's disease (CD).
Fanizza J, D'Amico F, Lauri G, Martinez-Dominguez SJ, Allocca M, Furfaro F, Zilli A, Fiorino G, Parigi TL, Radice S, Peyrin-Biroulet L, Danese S   +11 more
openaire   +3 more sources

Efficacy and safety of filgotinib for ulcerative colitis: A real‐world multicenter retrospective study in Japan

Alimentary Pharmacology and Therapeutics
While filgotinib, an oral Janus kinase (JAK) 1 preferential inhibitor, is approved for moderately to severely active ulcerative colitis (UC), real‐world studies assessing its short‐ and long‐term efficacy and safety are limited.
Shintaro Akiyama, K. Yokoyama, S. Yagi, S. Shinzaki, Kozo Tsuruta, S. Yoshioka, Minako Sako, Hiromichi Shimizu, Mariko Kobayashi, Toshiyuki Sakurai, Kei Nomura, T. Shibuya, M. Takahara, S. Hiraoka, Kyohei Sugai, S. Yanai, Atsushi Yoshida, M. Koroku, T. Omori, Masayuki Saruta, Takayuki Matsumoto, R. Okamoto, Kiichiro Tsuchiya, T. Fujii   +23 more
semanticscholar   +1 more source

Filgotinib Improves Experimental Pulmonary Fibrosis by Modulating JAK1/STAT3/SOCS3/IL‐17A Signalling

Basic & Clinical Pharmacology & Toxicology
Regulatory agencies in Europe and Japan have approved filgotinib, a selective JAK1 inhibitor, for use in treating rheumatoid arthritis, but its effect and mechanism of action in treating pulmonary fibrosis remain unclear.
Yunying Lv, Guanghua Zhang, Dexin Kong, Wanglin Jiang   +3 more
semanticscholar   +1 more source

P0611 Effectiveness comparisons between tofacitinib, filgotinib and upadacitinib in ulcerative colitis: results from the JAKARTA real-world evidence multicenter study

Journal of Crohn's & Colitis
As no direct comparisons exist, we compared the effectiveness of tofacitinib (TOFA), filgotinib (FILGO) and upadacitinib (UPA) in patients with Ulcerative Colitis (UC).
A. Buisson, X. Treton, M. Nachury, M. Uzzan, G. Bouguen, A. Banana Hamadidi, A. Amiot, M. Serrero, M. Fumery, L. Caillo, M. Hupé, B. Pereira, R. Altwegg   +12 more
semanticscholar   +1 more source

Filgotinib for the treatment of Crohn’s disease

Expert Opinion on Investigational Drugs, 2018
Inflammatory bowel diseases, such as Crohn's disease (CD) and ulcerative colitis (UC), are widespread diseases (with an estimated 2.2 million Europeans affected), and even populations previously considered 'low risk' (such as Japan and India) are witnessing an increasing incidence.
Labetoulle, Remi, Paul, Stéphane, Roblin, Xavier   +2 more
openaire   +4 more sources

P0662 Comparative effectiveness and safety of upadacitinib, tofacitinib, and filgotinib in patients with Ulcerative Colitis: analysis of whole and propensity score-matched data

Journal of Crohn's & Colitis
Moderate-to-severe Ulcerative Colitis (UC) often requires advanced treatments. Janus kinase (JAK) inhibitors, upadacitinib, tofacitinib, and filgotinib, have demonstrated efficacy in UC, though real-world comparisons remain limited.
L. Bertin, D. Scarabello, F. Zingone, E. Savarino, B. Barberio   +4 more
semanticscholar   +1 more source

Efficacy of Filgotinib in Moderate to Severe Ulcerative Colitis: A Prospective Study Using Partial Mayo Score, Ulcerative Colitis Endoscopic Index of Severity, and Geboes Histopathology Score

Crohn's & Colitis 360
Background/Aims Filgotinib (FIL), a Janus kinase inhibitor, shows clinical efficacy in moderate to severe ulcerative colitis (UC), but no prospective studies have examined endoscopic and histopathological outcomes.
Yoshiyuki Shirouzu, Hideki Ishibashi, Masayoshi Kage, Yutaro Mihara, Yuka Sakakibara, Kazuyoshi Nagata, Asami Suzuki, Toshihiro Ohmiya, Tomoko Irie, Yasumi Araki, K. Mitsuyama, H. Takedatsu, T. Noake   +12 more
semanticscholar   +1 more source

P0849 Real-world efficacy and safety of filgotinib in ulcerative colitis: results from the ENEIDA registry

Journal of Crohn's & Colitis
Ulcerative colitis (UC) is a chronic inflammatory disorder characterized by periods of relapse and remission. Current treatment options aim to achieve mucosal healing and sustain long-term remission, yet many patients experience treatment failure ...
I. Rodríguez-Lago, L. Cudero, C. Martínez Pascual, A. Minguez, R. Ferreiro-Iglesias, L. Arranz, A. Royo, D. Martín-Rodríguez, M. L. Mejías, M. Calafat, M. Calvo, C. Gargallo-Puyuelo, A. Granja, J. Santos-Fernández, P. Ucha, D. Ceballos, M. Martín-Arranz, I. Ferrer, L. Ramos, P. Almela, A. Fernández-Clotet, O. García-Bosch, J. Huguet, M. Lozano, S. Riestra, E. Sesé, G. Torres, A. M. Trapero, P. Varela, E. Domènech, M. Barreiro‐de Acosta   +30 more
semanticscholar   +1 more source

Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world study.

Intestinal Research
Background/Aims Real-world data on the use of filgotinib (FILGO) in patients with ulcerative colitis (UC) are limited. This study aims to provide consistent results on the effectiveness and safety of FILGO in treating UC.
A. Tursi, G. Mocci, F. Costa, L. Ceccarelli, E. Savarino, C. De Barba, C. Mucherino, Elvira D’Antonio, L. Montesano, M. Marzo, Franco Scaldaferri, D. Napolitano, Daniela Pugliese, A. G. Gravina, R. Pellegrino, R. Spagnuolo, Francesco Luzza, A. Cuomo, L. Donnarumma, G. Maconi, G. Cataletti, L. Bertani, G. Bodini, A. Pasta, S. Piergallini, M. Serio, A. Scarcelli, P. Capone, F. Cortellini, S. Rodino, L. Sebkova, G. Vespere, S. Sedda, Vittorio D’Onofrio, Leonardo De Luca, F. Gaiani, Stefano Kayali, Cristiano Pagnini, M. Graziani, M. D. Di Paolo, L. Allegretta, A. Cazzato, S. Scorza, A. Ferronato, D. Ribaldone, G. Aragona, P. Perazzo, G. Forti, M. Di Fonzo, F. Iacopini, R. Pica, C. Cassieri, F. M. Onidi, P. Usai Satta, W. Elisei, M. Picchio, Alfredo Papa   +56 more
semanticscholar   +1 more source